CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a targeted drug for melanoma, a rapidly increasing cancer. By optimizing a lead molecule that inhibits cancer cell growth, it seeks to provide a new treatment option that could significantly improve patient survival rates.
Melanoma is one of the fastest growing cancers worldwide, especially in regions with a high number of Caucasians such as Europe.
Currently, 100,000 diagnoses and 5,000 deaths from melanoma are registered in Europe every year.
This increase in melanoma incidence is a serious health problem and poses an economic as well as societal concern.
The survival in patients with malignant melanoma is very poor with a five year survival rate of about 10%.
Indeed, the current clinical therapies against malig…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
